VIMAC MILESTONE MEDICAL FUND
The VIMAC Milestone Medica Fund (VMM) is a life sciences venture capital fund providing equity financing to entrepreneurial companies. Their mission is to deliver long-term capital gains to investors as well as to the entrepreneurs who work at their portfolio companies. To achieve this objective, they invest in exceptional entrepreneurs with innovative ideas and the desire to create market-leading companies that build long-term sustainable value.
VIMAC MILESTONE MEDICAL FUND
Founded:
2003-01-01
Status:
Active
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2009-08-06 | Rapid Micro Biosystems | VIMAC Milestone Medical Fund investment in Series A - Rapid Micro Biosystems | 18.6 M USD |
| 2006-03-23 | Mimetogen Pharmaceuticals | VIMAC Milestone Medical Fund investment in Series A - Mimetogen Pharmaceuticals | N/A |
| 2005-12-12 | AngioChem | VIMAC Milestone Medical Fund investment in Venture Round - AngioChem | 6 M USD |
| 2005-02-02 | Neotropix | VIMAC Milestone Medical Fund investment in Series A - Neotropix | 10 M USD |
More informations about "VIMAC Milestone Medical Fund"
VIMAC Milestone Medical Fund - Crunchbase
The VIMAC Milestone Medica Fund (VMM) is a life sciences venture capital fund providing equity financing to entrepreneurial companies. Their mission is to deliver long-term capital gains to …See details»
VIMAC Milestone Medica: Fund Performance | PitchBook
Jan 7, 2004 · VIMAC Milestone Medica was a 2003 vintage venture capital fund managed by VIMAC Ventures. The fund was located in Boston, Massachusetts and invests in the United …See details»
VIMAC Milestone Medical Fund - Investments, Portfolio
Aug 6, 2009 · The VIMAC Milestone Medica Fund (VMM) is a life sciences venture capital fund providing equity financing to entrepreneurial companies.See details»
Vimac Ventures - Crunchbase Investor Profile & Investments
The life sciences team makes investments from the VIMAC Milestone Medica in early stage biotechnology and medical device companies. They lead or co-lead most investments and …See details»
MaRS takes big step in establishing Toronto as a major global R&D
MaRS Centre will become the primary location for NPS’s research and development activities in Canada while VIMAC will establish a business office in the centre for its VIMAC Milestone …See details»
Major international tenants give boost to Toronto R&D hub
May 17, 2004 · MaRS Centre will become the primary location for NPS’s research and development activities in Canada while VIMAC will establish a business office in the centre for …See details»
VIMAC Milestone Medical Fund - Unicorn Nest
Despite the VIMAC Milestone Medical Fund, startups are often financed by iNovia Capital, BDC Venture Capital. The meaningful sponsors for the fund in investment in the same round are …See details»
VIMAC Milestone Medica Fund - Tech in Asia
VIMAC Milestone Medica Fund deploys capital in early-stage companies located in the eastern U.S. and Canada. Today, the firm has two separate investment teams—one focused on early …See details»
VIMAC Milestone Medical Fund - BioCentury Company Profiles
VIMAC Milestone Medical Fund - BioCentury Company Profiles for the biopharma industrySee details»
Mimetogen Pharmaceuticals Inc. Closes Series A Financing and
Montréal, Québec — March 23rd, 2006 — Mimetogen Pharmaceuticals Inc. (“Mimetogen”), a privately held drug development company, announced today that it has successfully …See details»
Allergan Enters Into Licensing Agreement with Mimetogen …
Nov 4, 2015 · Under the terms of the agreement, Allergan will make an upfront payment of $50 million to Mimetogen and will fund phase 3 development of tavilermide. Mimetogen will …See details»
VIMAC Milestone Medical Fund - Updates, News, Events
The VIMAC Milestone Medica Fund (VMM) is a life sciences venture capital fund providing equity financing to entrepreneurial companies.See details»
Sena K. Biswas | MimetogenPharmaceuticals USA | United States of …
Biswas serves as Managing Director of VIMAC Milestone Medica Fund, L.P. Dr. Biswas joined the VIMAC Ventures as a Venture Partner in June 2002. Dr. Biswas specializes in life sciences …See details»
MITRAL at 5 Years: TMVR for MAC, Failing Devices Shows Ongoing …
May 19, 2023 · PARIS, France— Final, 5-year results of the MITRAL trial continue to support transcatheter mitral valve replacement (TMVR) in patients with failing bioprostheses or …See details»
Điện thoại Google Pixel Chính Hãng
THÔNG TIN CHỦ SỞ HỮU. Tên Doanh Nghiệp: CÔNG TY TNHH SONETS Địa điểm trụ sở chính: C12 Lô 12, Khu đô thị Định Công, Phường Định Công, Quận Hoàng Mai, Thành phố …See details»
Trang thông tin Phường Quận Hoàng Mai - Phường định công
Jul 13, 2024 · Tối ngày 15/8/2024, Phường Định Công đã tổ chức chương trình “ Liên hoan nghệ thuật quần chúng” với chủ đề “ Hà Nội niềm tin và hy vọng” chào mừng 79 năm cách mạng …See details»
Sena K. Biswas, PhD - Managing Director @ Vimac Ventures
Sena joined VIMAC as a Venture Partner in June of 2002 and became Managing Director, Life Sciences in January, 2003. Sena previously served as a Principal at TL Ventures, a leading …See details»
Phường Định Công - Cổng thông tin điện tử Quận Hoàng Mai
Aug 19, 2024 · Hòa chung không khí tưng bừng, phấn khởi của hàng triệu học sinh trong cả nước đón chào năm học mới. Sáng ngày 05 tháng 9 năm 2024, thầy và trò trường Tiểu học …See details»
AngioChem - Funding, Financials, Valuation & Investors
AngioChem develops new drugs that are capable of crossing the blood-brain barrier to treat brain diseases.See details»
Google Maps
Find local businesses, view maps and get driving directions in Google Maps.See details»